Longitudinal Modeling of Multiple Sclerosis using Continuous Time Models

Multiple sclerosis is a disease that affects the brain and spinal cord, it can lead to severe disability and has no known cure. The majority of prior work in machine learning for multiple sclerosis has been centered around using Magnetic Resonance Imaging scans or laboratory tests; these modalities are both expensive to acquire and can be unreliable. In a recent paper it was shown that disease progression can be predicted effectively using performance outcome measures (POMs) and demographic data. In our work we extend on this to focus on the modeling side, using continuous time models on POMs and demographic data to predict progression. We evaluate four continuous time models using a publicly available multiple sclerosis dataset. We find that continuous models are often able to outperform discrete time models. We also carry out an extensive ablation to discover the sources of performance gains, we find that standardizing existing features leads to a larger performance increase than interpolating missing features.

Disability prediction in multiple sclerosis using performance outcome measures and demographic data

Literature on machine learning for multiple sclerosis has primarily focused on the use of neuroimaging data such as magnetic resonance imaging and clinical laboratory tests for disease identification. However, studies have shown that these modalities are not consistent with disease activity such as symptoms or disease progression. Furthermore, the cost of collecting data from these modalities is high, leading to scarce evaluations. In this work, we used multi-dimensional, affordable, physical and smartphone-based performance outcome measures (POM) in conjunction with demographic data to predict multiple sclerosis disease progression. We performed a rigorous benchmarking exercise on two datasets and present results across 13 clinically actionable prediction endpoints and 6 machine learning models. To the best of our knowledge, our results are the first to show that it is possible to predict disease progression using POMs and demographic data in the context of both clinical trials and smartphone-base studies by using two datasets. Moreover, we investigate our models to understand the impact of different POMs and demographics on model performance through feature ablation studies. We also show that model performance is similar across different demographic subgroups (based on age and sex). To enable this work, we developed an end-to-end reusable pre-processing and machine learning framework which allows quicker experimentation over disparate MS datasets.